Why AI Projects Fail: Groundbreaking Survey Uncovers Crisis of Trust in Underlying Content
The survey revealed a make-or-break barrier to AI success with a whopping 61% of respondents pointing to erroneous or inconsistent answers as the top concern for broad AI adoption. In fact, Gartner warns that 100% of generative AI virtual customer assistant and virtual agent assistant projects that lack integration with modern KM systems will fail to meet their CX and operational cost-reduction goals.
'It is trusted content or bust when it comes to moving the needle with AI applications,' said Ashu Roy, eGain CEO.
'At a time when so many organizations are looking to AI to solve problems, it's important to stress that, with AI and knowledge, you need both to thrive,' said Marydee Ojala, Editor-in-Chief for KMWorld. 'The hard numbers from this study reveal how vital trusted content is to successful AI initiatives.'
With the eGain AI Knowledge Hub, Fortune 500 clients across industries such as banking, insurance, healthcare, and utilities have taken this trust-centric, knowledge-powered approach to accelerate AI initiatives.
'With trusted knowledge created and curated in the eGain AI knowledge Hub, we have been able to reduce AHT (Average Handle Time) by 24% and AWT (Average Wait Time) by 57% for member calls,' said Amy Durst, Assistant VP of Internal Support at Rogue Credit Union. 'At the same time, our agent satisfaction scores went up by 22%.'
More information
About eGain
eGain AI Knowledge Hub helps businesses improve customer experience and reduce cost by delivering trusted, consumable answers.
Contact eGain Media Relations [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
HIVE Digital Technologies Ltd (HIVE) Q1 2026 Earnings Call Highlights: Record Revenue and ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points HIVE Digital Technologies Ltd (NASDAQ:HIVE) reported a record quarter with over $45 million in total revenue, primarily driven by Bitcoin mining operations. The company achieved a significant growth in earnings per share, increasing by 206% year over year. HIVE's strategic expansion in Paraguay has been transformative, allowing the company to rapidly scale its Bitcoin mining operations. The company maintains a strong balance sheet with $24.6 million in cash and $47.3 million in digital currencies. HIVE's focus on renewable energy and sustainable practices positions it well for future growth, particularly in the AI and HPC sectors. Negative Points The volatility of Bitcoin prices poses a risk to HIVE's financial performance, as evidenced by the significant non-cash reevaluation of Bitcoin on their balance sheet. High depreciation charges due to the purchase of new GPU and ASIC chips for AI and Bitcoin buildout could impact profitability. The company's expansion and scaling efforts require significant capital investment, which could strain financial resources if not managed carefully. HIVE's growth strategy involves complex operations across multiple countries, which may present logistical and regulatory challenges. The competitive landscape in the Bitcoin mining and AI sectors is intensifying, which could pressure HIVE's market position and margins. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with HIVE. Q: Can you provide an overview of HIVE's financial performance for Q1 2026? A: Aiden Killick, President and CEO, highlighted that HIVE had a record quarter with over $45 million in total revenue, 90% of which came from Bitcoin mining operations and 10% from their HPC AI business. The company achieved a gross operating margin of 38%, yielding about $15.8 million in cash flow from operations, and reported a net income of $35 million with $44.6 million in adjusted EBITDA. Q: How is HIVE managing its Bitcoin holdings and what strategies are in place for future growth? A: Aiden Killick explained that HIVE ended the quarter with 435 Bitcoin on the balance sheet and has a Bitcoin pledge strategy allowing them to purchase Bitcoin back at zero interest. This strategy has enabled HIVE to scale its Bitcoin mining business without dilution or taking on debt, effectively using $200 million worth of CapEx. Q: What are the key developments in HIVE's expansion efforts, particularly in Paraguay? A: Aiden Killick noted that HIVE has significantly expanded its operations in Paraguay, completing phase one of their expansion ahead of schedule. They are currently operating at over 15 exahash and are fully funded to reach 25 exahash by American Thanksgiving. This expansion is part of their strategy to maintain a 440 megawatt green energy footprint for Bitcoin mining. Q: How does HIVE's AI and HPC business contribute to its overall strategy? A: Craig Tavares, President of Buzz HPC, explained that HIVE's AI and HPC business is rapidly scaling, with a target of reaching $100 million ARR. The company operates over 5,000 GPUs and is focused on providing a full suite of infrastructure services for AI, leveraging their existing data centers and renewable energy sources. Q: What are HIVE's future plans for data center expansion and AI infrastructure? A: Craig Tavares mentioned that HIVE is expanding its data center footprint with recent acquisitions in Toronto and Sweden. These facilities will support their sovereign AI strategy and are expected to go live next year. The Toronto data center, in particular, will be a tier 3 facility leveraging liquid cooling infrastructure to support high-density GPU clusters. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
White House AI czar David Sacks says 'AI psychosis' is similar to the 'moral panic' of social media's early days
The White House AI advisor discussed "AI psychosis" on a recent podcast. David Sacks said he doubted the validity of the concept. He compared it to the "moral panic" that surrounded earlier tech leaps, like social media. AI can create a diet plan, organize a calendar, and provide answers to an endless variety of burning questions. Can it also cause a psychiatric breakdown? David Sacks, the White House official spearheading America's AI policies, doesn't think so. President Donald Trump's AI and crypto czar discussed "AI psychosis" during an episode of the "All-In Podcast" published Friday. While most people engage with chatbots without a problem, a small number of users say the bots have encouraged delusions and other concerning behavior. For some, ChatGPT serves as an alternative to professional therapists. A psychiatrist earlier told Business Insider that some of his patients exhibiting what's been described as "AI psychosis," a nonclinical term, used the technology before experiencing mental health issues, "but they turned to it in the wrong place at the wrong time, and it supercharged some of their vulnerabilities." During the podcast, Sacks doubted the whole concept of "AI psychosis." "I mean, what are we talking about here? People doing too much research?" he asked. "This feels like the moral panic that was created over social media, but updated for AI." Sacks then referred to a recent article featuring a psychiatrist, who said they didn't believe using a chatbot inherently induced "AI psychosis" if there aren't other risk factors — including social and genetic — involved. "In other words, this is just a manifestation or outlet for pre-existing problems," Sacks said. "I think it's fair to say we're in the midst of a mental health crisis in this country." Sacks attributed the crisis instead to the COVID-19 pandemic and related lockdowns. "That's what seems to have triggered a lot of these mental health declines," he said. After several reports of users suffering mental breaks while using ChatGPT, OpenAI CEO Sam Altman addressed the issue on X after the company rolled out the highly anticipated GPT-5. "People have used technology, including AI, in self-destructive ways; if a user is in a mentally fragile state and prone to delusion, we do not want the AI to reinforce that," Altman wrote. "Most users can keep a clear line between reality and fiction or role-play, but a small percentage cannot." Earlier this month, OpenAI introduced safeguards in ChatGPT, including a prompt encouraging users to take breaks after long conversations with the chatbot. The update will also change how the chatbot responds to users asking about personal challenges. Read the original article on Business Insider Solve the daily Crossword
Associated Press
an hour ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
